Skip to main content

Table 7 Correlation between disease characteristics and PET-based therapeutic response in the study population

From: Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma

 Objective response by PERCISTTest value*P valueSig.
CMRPMRSMDPMD
No. = 18No. = 9No. = 2No. = 4
Pathology
NHL10 (55.6%)1 (11.1%)1 (50.0%)3 (75.0%)7.8940.246NS
HL7 (38.9%)8 (88.9%)1 (50.0%)1 (25.0%)
GALT1 (5.6%)0 (0.0%)0 (0.0%)0 (0.0%)
Location
NA3 (16.7%)0 (0.0%)0 (0.0%)1 (25.0%)3.9000.690NS
Supra7 (38.9%)6 (66.7%)1 (50.0%)1 (25.0%)
Supra & infra8 (44.4%)3 (33.3%)1 (50.0%)2 (50.0%)
Stage
I1 (5.6%)1 (11.1%)0 (0.0%)0 (0.0%)14.5060.696NS
IE1 (5.6%)0 (0.0%)0 (0.0%)0 (0.0%)
II5 (27.8%)5 (55.6%)1 (50.0%)0 (0.0%)
IIE1 (5.6%)0 (0.0%)0 (0.0%)0 (0.0%)
III2 (11.1%)1 (11.1%)0 (0.0%)2 (50.0%)
IIIS5 (27.8%)1 (11.1%)1 (50.0%)0 (0.0%)
IV3 (16.7%)1 (11.1%)0 (0.0%)2 (50.0%)
New lesion
Absent18 (100.0%)9 (100.0%)2 (100.0%)0 (0.0%)33.000.000HS
Present0 (0.0%)0 (0.0%)0 (0.0%)4 (100.0%)
  1. P value > 0.05 Non significant (NS), P value < 0.05 Significant (S), P value < 0.01 Highly significant (HS)
  2. *Chi-square test